Global Sepsis Treatment Market - 2022-2029

Market Overview

The global sepsis treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Antibiotics are the most common treatment for sepsis, severe sepsis, and septic shock. Antibiotics will be given directly into a vein if severe sepsis and septic shock (intravenously).

Market Dynamics

The factors influencing the global sepsis treatment market are the increasing research and development, and the growing incidence of sepsis is expected to drive the market.

The increasing research and development are expected to drive the market the growth

In an adult intensive care units, sepsis and septic shock with subsequent multi-organ failure are currently the leading causes of death (ICUs). Even though surgical and pharmacological approaches to sepsis treatment are improving, epidemiological studies show that the incidence of sepsis has increased over the last 20 years. The high prevalence of sepsis and its high economic impact have prompted the development of several projects to improve recognition and accurately describe the disease's course over the last few decades. For instance, new research offers much-needed hope for sepsis treatment. A compound called cilengitide was tested in a preclinical trial by researchers at the Royal College of Surgeons in Ireland (RCSI) in Dublin. InnovoSep is the brand name for the drug. InnovoSep was successfully used in the preclinical trial to prevent S. aureus and E. coli from binding to human endothelial cells both in vivo and in vitro. InnovoSep prevented the infection from progressing to septic shock and organ failure by preventing damage to endothelial cells. Despite recent advances in critical care, severely septic patients suffer from high morbidity and mortality. The development of new treatments has been accelerated, including complex interactions between the inflammatory, coagulation, and fibrinolytic systems. The only FDA-approved medicine for severe sepsis is recombinant human activated protein C (rhAPC), also known as drotrecogin alfa (activated) (DAA). Hence, the increasing research and development for sepsis treatment are expected to drive the market growth.

The side effects associated with sepsis treatment are expected to hamper the market growth

Sepsis is a life-threatening medical condition. Because survival is dependent on medications, side effects aren't always a major concern. All treatment protocols include de-escalation of antibiotics and other medications when certain conditions are met to reduce side effects. Injection site reactions such as pain, redness, and swelling are common with antibiotic injections. Antibiotics, in general, cause stomach upset, intestinal problems, nausea, and loss of appetite in the digestive system.

Antibiotics cause the most allergic reactions, so the patient's antibiotic history will determine which drugs can be used. Mood and behaviour changes, aggressiveness (rare but possible), increased appetite, weight gain, and high blood pressure are just a few corticosteroid injections' unpleasant and common side effects. Vasopressors constrict blood vessels quickly, acting as mild positive inotropes, causing the heart to beat faster. Most people will experience significant and life-threatening side effects such as anxiety, nervousness, rapid heartbeats, breathing difficulties, headaches, weakness, and dizziness. Heart attack or stroke is the most serious but rare side effect.

COVID-19 Impact Analysis

The COVID-19 outbreak has hampered several industries. As a result of COVID-19, several countries have declared a state of emergency with strict regulations. Due to this, people were stranded in their current locations. However, the healthcare sector is unaffected; however, the market for sepsis therapeutics has seen a slowdown in growth. Because of the widespread fear of COVID-19, only those suffering from severe sepsis were willing to risk visiting hospitals, clinics, or other services. As a result, the growth of the sepsis treatment market has been hampered.

Moreover, COVID-19, according to the Global Sepsis Alliance, can cause sepsis, the body's overpowering and life-threatening response to an infection that can result in organ damage and death. In the United States, sepsis kills one out of three patients who die in a hospital. Various infections can cause sepsis, but pneumonia is the most common. Pneumonia is a severe lung inflammation caused by an infection in which the air sacs fill with pus and make breathing difficult. Pneumonia and sepsis can be caused by bacterial, viral, or fungal infections. COVID-19 may cause sepsis due to various factors, including direct viral invasion, the presence of a bacterial or viral co-infection, and/or the patient's age. Hence, with increasing covid-19 cases, the demand for sepsis treatment is also expected to increase.

Segment Analysis

The antibiotics segment is expected to dominate the global sepsis treatment market

Antibiotics should be given intravenously in sufficient doses to achieve bactericidal serum levels. Many studies have found that the achievement of serum bactericidal levels, rather than the number of antibiotics given, correlates with clinical improvement. The rising prevalence of MRSA must be considered when choosing empiric antibiotics, and an agent such as vancomycin or linezolid should be included. This is especially true in patients who have previously used IV drugs, have indwelling vascular catheters or devices, or have recently been hospitalized. In patients with intra-abdominal or perineal infections, antianaerobic coverage is recommended. Patients with sepsis should almost always be admitted to the hospital, where they will be given intravenous antibiotics (usually broad-spectrum) and therapy to support any organ dysfunction.

According to statistics, sepsis can quickly cause organ damage and death; delay in receiving antibiotics can result in a 7% increase in mortality per hour in severe sepsis. In a hospital's intensive care unit, critical care medicine specialists, infectious disease specialists, and others, as needed, treat most cases of sepsis (ICU). Two- or three-antibiotic combinations given simultaneously are appropriate antibiotics for sepsis; most combinations include vancomycin to treat many MRSA and other antibiotic-resistant (drug-resistant) infections. Antibiotics are antibiotics that are commonly used. Some of the antibiotics used for sepsis are ceftriaxone (Rocephin), meropenem (Merrem), ceftazidime (Fortaz), cefotaxime (Claforan), cefepime (Maxipime), piperacillin and tazobactam (Zosyn), ampicillin and sulbactam (Unasyn), imipenem/cilastatin (Primaxin), levofloxacin (Levaquin), and clindamycin (Cleocin).

Geographical Analysis

North America region is expected to hold the largest market share in the global sepsis treatment market

In the United States and Canada, sepsis has a high prevalence and is on the rise. The presence of major players in the region is also expected to drive market growth. Each year, sepsis affects approximately 1.7 million adults in the United States, potentially resulting in over 250 000 deaths. According to various studies, sepsis is present in 30 to 50 percent of hospitalizations that result in death. The high prevalence of sepsis and the belief that most sepsis-related deaths could be avoided with better care have sparked a slew of sepsis performance improvement initiatives in hospitals worldwide.

In the United States, sepsis affects about 1.7 million adults each year. The US Food and Drug Administration has granted fast track designation to Inotrem's nangibotide program, which is being developed for the treatment of septic shock (FDA). The active ingredient in Nangibotide is LR12. LR12 is a 12-amino-acid peptide that blocks the expression of the triggering receptor on myeloid cells 1 (TREM-1). In preclinical models, nangibotide improved survival after septic shock by restoring the required inflammatory response and vascular function.

Competitive Landscape

The global sepsis treatment market is moderately competitive with mergers, collaborations, and product launches. Some key players are F. Hoffmann-La Roche Ltd, Asahi Kasei Corporation, Xellia Pharmaceuticals, Pfizer Inc.

Asahi Kasei Corporation

Overview: Asahi Kasei Corporation is a Japanese chemical conglomerate. Chemicals and materials science are its main products. It was established in May of 1931.

Product Portfolio: The SCARLET study, a phase 3 multinational trial, looked at the efficacy and safety of a recombinant human soluble thrombomodulin (ART-123) to treat sepsis-associated coagulopathy (SAC), which is linked to increased mortality risk in sepsis patients.

Key Development: By 2021, Asahi Kasei Corporation plans to release ART-123 for the treatment of sepsis.

Why Purchase the Report?

Visualize the composition of the global sepsis treatment market segmentation by drug type, by application, and end-user highlighting the key commercial assets and players.

Identify commercial opportunities in global sepsis treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global sepsis treatment market - level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global sepsis treatment market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers